Transferases

GSTS Expands OCIANA™ Port Optimization Consortium

Retrieved on: 
Tuesday, July 13, 2021
Information technology management, Glutathione S-transferase, Transferases, Business process management

OCIANA is an artificial intelligence (AI) based system developed by GSTS that rapidly processes satellite data with other data sets harvested from ocean, weather, and port activity to provide dynamic decision-making information in near real-time.

Key Points: 
  • OCIANA is an artificial intelligence (AI) based system developed by GSTS that rapidly processes satellite data with other data sets harvested from ocean, weather, and port activity to provide dynamic decision-making information in near real-time.
  • The capabilities include improved port and vesselefficiency, emission reduction, enhanced environmental protection and endangered marine species protection.
  • OCIANAis a modular platform that is configured to the specific operational, geographic, and regulatory conditions of each port, providing unparalleled performance in accuracy and optimization.
  • "The engagement with the new Consortium members will enable GSTS to demonstrate the flexibility of OCIANA to adjust and adapt to the operational and geographic conditions of any port in the world.

Glucosylceramide Synthase Inhibitors Pipeline Insight Report 2021 Featuring Idorsia Pharmaceuticals & Sanofi and Lucerastat, Venglustat & Sinbaglustat - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021
Pharmaceutical, Health, Clinical trials, Transferases, Ceramide glucosyltransferase, Glucocerebroside, Drug pipeline

b'The "Glucosylceramide Synthase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis "Glucosylceramide synthase inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Glucosylceramide synthase inhibitors pipeline landscape.

Key Points: 
  • b'The "Glucosylceramide Synthase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis "Glucosylceramide synthase inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Glucosylceramide synthase inhibitors pipeline landscape.
  • It further highlights the inactive pipeline products in this space.\nThe companies and academics are working to assess challenges and seek opportunities that could influence Glucosylceramide synthase inhibitors R&D.
  • The therapies under development are focused on novel approaches for Glucosylceramide synthase inhibitors.\nThis segment of the Glucosylceramide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • The companies which have their Glucosylceramide synthase inhibitors drug candidates in the most advanced stage, i.e.

Improving stroke treatment with a modified therapeutic molecule

Retrieved on: 
Thursday, February 18, 2021
Branches of biology, Glutamates, Neurotransmitters, Hepatology, Transaminase, Transferases, Glutamate, Glutamate–glutamine cycle, Glutamic acid

The research team aimed at developing an effective treatment that would compensate for the increase in glutamate.

Key Points: 
  • The research team aimed at developing an effective treatment that would compensate for the increase in glutamate.
  • "Unlike other drugs, our molecule does not need to cross the blood-brain barrier to achieve its therapeutic effect.
  • The modified molecule, glutamate-oxaloacetate transaminase (GOT), is already known for its therapeutic effects.
  • The research team now intends to observe the longer-term effect of the molecule and explore applications to other neuronal diseases.

GSTS Awarded Contribution for Artificial Intelligence Fusion of Satellite Data

Retrieved on: 
Tuesday, November 24, 2020
Articles, Glutathione S-transferase, Transferases, Artificial intelligence, Science and technology, Academic disciplines

This capability will incorporate data fusion of current and future satellite data sets along with environmental data and apply the power of machine learning to satisfy unique user needs.

Key Points: 
  • This capability will incorporate data fusion of current and future satellite data sets along with environmental data and apply the power of machine learning to satisfy unique user needs.
  • GSTS's prediction capability will augment operator decision-making by delivering actionable intelligence in near real-time.
  • "This capability will enable GSTS to expand our growing AI solutions by fusing current and next generation satellite data sets, enabling game-changing results," said Richard Kolacz, GSTS CEO.
  • GSTS is a leader in Artificial Intelligence solutions for the maritime domain.

GSTS Awarded Contract to Support Maritime Risk Mitigation

Retrieved on: 
Thursday, September 17, 2020
Articles, Academic disciplines, Actuarial science, Security, Glutathione S-transferase, Transferases, Artificial intelligence, Risk management, Risk

GSTS will leverage OCIANA's robust risk management capabilities to support maritime risk mitigation.

Key Points: 
  • GSTS will leverage OCIANA's robust risk management capabilities to support maritime risk mitigation.
  • This contract award will enable the Department of National Defence to test OCIANA, an AI-based Maritime Information Management platform.
  • "Protecting all of Canada's maritime approaches and points of entry, from coast to coast to coast, OCIANA's maritime AI-based risk management capabilities will support real-time decision-making and response capabilities," said Richard Kolacz, GSTS CEO.
  • In this case, we have developed a unique AI solution to support the identification of vessels representing a potential COVID-19 risk in addition to the security risk parameters.

GSTS awarded contribution for Space-Based Artificial Intelligence

Retrieved on: 
Tuesday, August 4, 2020
Science and technology, Articles, Technology, Glutathione S-transferase, Transferases, Artificial intelligence

"This contribution will enable GSTS to expand our growing AI capabilities into the space sector to support decision making based on the same techniques we utilize in the maritime domain, enabling detection, recognition and prediction," said Richard Kolacz, GSTS CEO.

Key Points: 
  • "This contribution will enable GSTS to expand our growing AI capabilities into the space sector to support decision making based on the same techniques we utilize in the maritime domain, enabling detection, recognition and prediction," said Richard Kolacz, GSTS CEO.
  • Computer vision involves the automatic extraction, analysis and understanding of information gleaned from digital images.
  • GSTS is a leader in Artificial Intelligence solutions for the maritime domain.
  • SOURCE GLOBAL SPATIAL TECHNOLOGY SOLUTIONS INC. (GSTS)

New canine study investigates cancers and exposure to environmental chemicals

Retrieved on: 
Friday, April 10, 2020
Chemistry, Physical sciences, Natural sciences, Toxicology, Glutathione S-transferase, Transferases, Toxicity, Cancer, Selenium, Transferase, Glutathione S-transferase A1

Morris Animal Foundation -funded researchers at the University of Wisconsin-Madison are studying how exposure to common environmental chemicals, like those found in tobacco smoke and yard products, and individual genetic differences in response to them, put dogs at risk for common cancers.

Key Points: 
  • Morris Animal Foundation -funded researchers at the University of Wisconsin-Madison are studying how exposure to common environmental chemicals, like those found in tobacco smoke and yard products, and individual genetic differences in response to them, put dogs at risk for common cancers.
  • When dogs or humans are exposed to toxic chemicals in the environment, glutathione-S-transferase (GST) enzymes in the liver help neutralize those chemicals.
  • Due to genetic variations in GST enzymes, people vary in their capacity to deactivate environmental hazards.
  • If these individuals ingest or inhale toxic chemicals, this inability can result in cancer development over repeated exposures.

Global and Chinese Market Glutamic Pyruvic Transaminase (GPT) Market Insights, 2014-2019 & 2019-2024 by Manufacturers, Product Type, Application, and Technology - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 11, 2019
Biotechnology, Manufacturing, Health, Chemicals, Plastics, Enzymes, Carboxylic acids, Glutamate, Hepatology, Transaminase, Transferases, Flavor enhancers, GPT, Aspartate transaminase, Glutamic acid, GPT2

The "Glutamic Pyruvic Transaminase (GPT) Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glutamic Pyruvic Transaminase (GPT) Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.
  • Glutamic Pyruvic Transaminase (GPT) Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Glutamic Pyruvic Transaminase (GPT) industry with a focus on the Chinese market.
  • Overall, the report provides an in-depth insight of 2014-2024 Global and Chinese Glutamic Pyruvic Transaminase (GPT) market covering all important parameters.
  • 5.2 Market Competition of Glutamic Pyruvic Transaminase (GPT) Industry by Country (USA, EU, Japan, Chinese etc.)

Glucosylceramide Synthase Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 8, 2019
Health, Pharmaceutical, Health sciences, Pharmaceutical sciences, Ceramide glucosyltransferase, Transferases, Glucocerebroside, Drug pipeline, Mechanism of action, Chemistry

The "Glucosylceramide Synthase Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glucosylceramide Synthase Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Glucosylceramide Synthase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Glucosylceramide Synthase Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Glucosylceramide Synthase Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine

Fatty Acid Synthase (FAS) Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 8, 2019
Manufacturing, Chemicals, Plastics, Enzymes, Catalysts, Fatty acids, Fatty acid synthase, Metabolism, Transferases, Beta-ketoacyl-(acyl-carrier-protein) synthase III

The "Fatty Acid Synthase (FAS) Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fatty Acid Synthase (FAS) Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Fatty Acid Synthase (FAS) Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Synthase (FAS) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Fatty Acid Synthase (FAS) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine